Recbio First Biotech To Brave A Hong Kong IPO In 2022
mRNA Contender For Omicron?
Executive Summary
Chinese vaccine maker Recbio hopes an IPO in Hong Kong will bring investor attention to its mRNA COVID vaccine with potential against the Omicron variant.